Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for
inhalation in patients with chronic obstructive airways disease in daily practice
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fenoterol Fenoterol, ipratropium drug combination Ipratropium Pharmaceutical Solutions